Theragen Etex Co.Ltd

KQ:066700 Korea Pharmaceuticals
Market Cap
$54.85 Million
₩80.30 Billion KRW
Market Cap Rank
#21459 Global
#1019 in Korea
Share Price
₩2635.00
Change (1 day)
+0.00%
52-Week Range
₩2460.00 - ₩3315.00
All Time High
₩21800.00
Categories
Companies in Korea Pharmaceuticals
About

Theragen Etex Co.,Ltd., together with its subsidiaries, engages in the research and development, production, and sale of pharmaceutical products. It offers drugs in the fields of circulatory, respiratory, digestive, antibiotics, antifungals, analgesic, endocrine and metabolic, hepatoprotective, psychotropic, urinary system, skeletal muscle, PMS, anthelmintic, nutrition, and others. The company wa… Read more

Theragen Etex Co.Ltd (066700) - Net Assets

Latest net assets as of September 2025: ₩145.00 Billion KRW

Based on the latest financial reports, Theragen Etex Co.Ltd (066700) has net assets worth ₩145.00 Billion KRW as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩245.25 Billion) and total liabilities (₩100.25 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets ₩145.00 Billion
% of Total Assets 59.12%
Annual Growth Rate 14.47%
5-Year Change -65.11%
10-Year Change 89.68%
Growth Volatility 47.24

Theragen Etex Co.Ltd - Net Assets Trend (2005–2024)

This chart illustrates how Theragen Etex Co.Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Theragen Etex Co.Ltd (2005–2024)

The table below shows the annual net assets of Theragen Etex Co.Ltd from 2005 to 2024.

Year Net Assets Change
2024-12-31 ₩130.54 Billion -14.64%
2023-12-31 ₩152.93 Billion +6.50%
2022-12-31 ₩143.60 Billion -35.52%
2021-12-31 ₩222.70 Billion -40.47%
2020-12-31 ₩374.12 Billion +175.37%
2019-12-31 ₩135.86 Billion +67.90%
2018-12-31 ₩80.92 Billion -6.91%
2017-12-31 ₩86.93 Billion +20.55%
2016-12-31 ₩72.10 Billion +4.77%
2015-12-31 ₩68.82 Billion -16.06%
2014-12-31 ₩82.00 Billion +2.93%
2013-12-31 ₩79.67 Billion +11.00%
2012-12-31 ₩71.77 Billion +27.80%
2011-12-31 ₩56.16 Billion +14.16%
2010-12-31 ₩49.19 Billion +8.28%
2009-12-31 ₩45.43 Billion +73.38%
2008-12-31 ₩26.20 Billion +41.17%
2007-12-31 ₩18.56 Billion +61.50%
2006-12-31 ₩11.49 Billion +14.76%
2005-12-31 ₩10.01 Billion --

Equity Component Analysis

This analysis shows how different components contribute to Theragen Etex Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 1087454590000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Other Components ₩123.02 Billion 109.70%
Total Equity ₩112.15 Billion 100.00%

Theragen Etex Co.Ltd Competitors by Market Cap

The table below lists competitors of Theragen Etex Co.Ltd ranked by their market capitalization.

Company Market Cap
PT Cakra Buana Resources Energ
JK:CBRE
 		$47.72 Million
Jagran Prakashan Limited
NSE:JAGRAN
 		$47.74 Million
Tri Ocean Textile Co Ltd
TW:1472
 		$47.78 Million
Electra Battery Materials Corp
NASDAQ:ELBM
 		$47.78 Million
Zhejiang Taimei Medical Technology Co., Ltd.
F:A2V
 		$47.71 Million
Treasury Metals Inc
F:TRC1
 		$47.70 Million
Wielton S.A.
WAR:WLT
 		$47.70 Million
Mayfield Group Holdings Ltd
AU:MYG
 		$47.70 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Theragen Etex Co.Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 135,701,179,010 to 112,146,086,090, a change of -23,555,092,920 (-17.4%).
  • Net loss of 40,984,882,190 reduced equity.
  • Dividend payments of 99,135,600 reduced retained earnings.
  • Other factors increased equity by 17,528,924,870.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income ₩-40.98 Billion -36.55%
Dividends Paid ₩99.14 Million -0.09%
Other Changes ₩17.53 Billion +15.63%
Total Change ₩- -17.36%

Book Value vs Market Value Analysis

This analysis compares Theragen Etex Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.75x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 1.00x to 0.75x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2016-12-31 ₩2634.83 ₩2635.00 x
2017-12-31 ₩2908.53 ₩2635.00 x
2018-12-31 ₩2657.75 ₩2635.00 x
2019-12-31 ₩4445.60 ₩2635.00 x
2020-12-31 ₩11711.29 ₩2635.00 x
2021-12-31 ₩6958.10 ₩2635.00 x
2022-12-31 ₩4486.69 ₩2635.00 x
2023-12-31 ₩4239.95 ₩2635.00 x
2024-12-31 ₩3503.98 ₩2635.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Theragen Etex Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -36.55%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -16.42%
  • • Asset Turnover: 1.05x
  • • Equity Multiplier: 2.11x
  • Recent ROE (-36.55%) is below the historical average (0.06%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2009 0.86% 0.46% 0.69x 2.69x ₩-3.00 Billion
2010 2.16% 1.18% 0.82x 2.22x ₩-3.46 Billion
2013 1.79% 1.46% 0.75x 1.63x ₩-6.08 Billion
2014 2.10% 1.50% 0.85x 1.65x ₩-6.02 Billion
2015 -11.87% -8.26% 0.72x 2.00x ₩-15.05 Billion
2016 3.09% 2.20% 0.72x 1.95x ₩-4.98 Billion
2017 1.47% 1.18% 0.74x 1.67x ₩-7.42 Billion
2018 -12.63% -8.70% 0.67x 2.16x ₩-18.31 Billion
2019 32.13% 31.61% 0.57x 1.78x ₩30.06 Billion
2020 -2.40% -6.27% 0.27x 1.43x ₩-46.38 Billion
2021 -5.32% -7.12% 0.48x 1.57x ₩-34.12 Billion
2022 6.66% 5.01% 0.77x 1.72x ₩-4.80 Billion
2023 19.32% 12.11% 0.89x 1.79x ₩12.64 Billion
2024 -36.55% -16.42% 1.05x 2.11x ₩-52.20 Billion

Industry Comparison

This section compares Theragen Etex Co.Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.

Industry Context

  • Industry: Pharmaceuticals
  • Average net assets among peers: $96,196,506,488
  • Average return on equity (ROE) among peers: -9.52%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Theragen Etex Co.Ltd (066700) ₩145.00 Billion 0.86% 0.69x $47.71 Million
Sam Chun Dang Pharm. Co. Ltd (000250) $114.32 Billion 10.17% 0.61x $3.69 Billion
DongKoo Bio&Pharma Co. Ltd (006620) $94.65 Billion 9.66% 0.53x $57.77 Million
NatureCell Co.Ltd (007390) $34.02 Billion -9.48% 0.55x $37.82 Million
Sam-A Pharm. Co. Ltd (009300) $148.92 Billion 6.63% 0.09x $21.27 Million
Kyung Dong Pharmaceutical Co. Ltd (011040) $257.20 Billion 4.73% 0.21x $50.06 Million
WooGene B&G Co. Ltd (018620) $26.51 Billion -25.02% 1.26x $10.61 Million
Oscotec Inc (039200) $28.83 Billion -91.10% 0.70x $890.75 Million
EstechPharma Co. Ltd (041910) $123.30 Billion 5.58% 0.09x $50.99 Million
Komipharm International Co. Ltd (041960) $93.39 Billion -15.32% 0.50x $237.27 Million
Eagle Veterinary Technology Co.Ltd (044960) $40.83 Billion 8.91% 0.29x $20.48 Million